Benign Prostatic Hyperplasia Devices

View All

MedTech News for Medtronic, Cala, Medline, Rivermark Medical
Medtronic Announced World’s First Approval for MiniMed 780G System; CE Mark for Medtronic’s Next Generation Micra Leadless Pacing Systems; Biosense Webster Received Approval for VARIPULSE PFA Platform; Rivermark Medical Updated on Flostent System; Cala Disclosed TAPS Therapy Data for Essential Tremor; Medline Introduced Transparent Wound Dressing

Medtronic Received CE Mark for its Next Generation Micra Leadless Pacing Systems On January 5, 2024, Medtronic announced that the Micra AV2 and Micra VR2, the next generation of its industry-leading tiny, leadless pacemakers, earned the CE (Conformité Européenne) Mark. The world's tiniest pacemakers, the rMic...

Find More

Benign Prostatic Hyperplasia Devices Market
Market Heats Up as Managing Benign Prostatic Hyperplasia Through Devices Gains Traction

Benign prostatic hyperplasia, also called Benign prostatic hypertrophy or Benign prostatic obstruction, is a common condition in men as they get older. The prostate gland is a walnut-shaped gland present in men's reproductive systems, and its primary purpose is to produce a fluid that is secreted into semen. The pr...

Find More